Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × INDUSTRY × evolocumab × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Endocrine Neoplasia Type 1 1 Coronary Disease 1

Interventions

Carboplatin 258 Paclitaxel 253 Cisplatin 204 Docetaxel 202 pembrolizumab 181 Gemcitabine 174 Pemetrexed 130 Rituximab 121 Capecitabine 118 Bevacizumab 115 Dexamethasone 99 Fluorouracil 92 Cyclophosphamide 88 Doxorubicin 87 Trastuzumab 81 Prednisone 81 Nivolumab 77 Oxaliplatin 71 atezolizumab 62 durvalumab 59 Injections 58 Lenalidomide 55 Leucovorin 54 130-nm albumin-bound paclitaxel 54 Irinotecan 47 Fulvestrant 45 Drug Therapy 45 Bortezomib 44 Letrozole 43 Bendamustine Hydrochloride 41

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03872401 2025-11-10

VESALIUS-CV

Amgen

Phase 3 Completed

12,301 enrolled

Coronary Disease, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡